Michael J. Rossi - Jan 17, 2025 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
PRESIDENT & CEO, Director
Signature
/s/ John LaRocca, Attorney-in-Fact
Stock symbol
YMAB
Transactions as of
Jan 17, 2025
Transactions value $
$0
Form type
4
Date filed
1/22/2025, 07:00 PM
Previous filing
Feb 14, 2024
Next filing
Mar 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +105K +294.96% $0.00 141K Jan 17, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +211K $0.00 211K Jan 17, 2025 Common Stock 211K $6.16 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2026, January 17, 2027 and January 17, 2028, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2 Represents stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan.
F3 The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 17, 2026, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.